Chicago Capital LLC Has $21.04 Million Position in PROCEPT BioRobotics Co. (NASDAQ:PRCT)

Chicago Capital LLC boosted its holdings in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT) by 12.7% in the third quarter, Holdings Channel.com reports. The fund owned 262,651 shares of the company’s stock after buying an additional 29,668 shares during the quarter. Chicago Capital LLC’s holdings in PROCEPT BioRobotics were worth $21,044,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in PRCT. Wellington Management Group LLP grew its stake in shares of PROCEPT BioRobotics by 32.4% during the fourth quarter. Wellington Management Group LLP now owns 1,065,698 shares of the company’s stock worth $44,663,000 after purchasing an additional 260,946 shares during the period. Vanguard Group Inc. grew its position in shares of PROCEPT BioRobotics by 2.7% during the 4th quarter. Vanguard Group Inc. now owns 4,184,585 shares of the company’s stock worth $175,376,000 after buying an additional 109,694 shares during the period. Diversified Trust Co increased its stake in shares of PROCEPT BioRobotics by 25.4% in the 1st quarter. Diversified Trust Co now owns 13,442 shares of the company’s stock valued at $664,000 after acquiring an additional 2,725 shares during the last quarter. Allspring Global Investments Holdings LLC raised its position in shares of PROCEPT BioRobotics by 23.0% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 199,027 shares of the company’s stock valued at $9,836,000 after acquiring an additional 37,179 shares during the period. Finally, Principal Financial Group Inc. boosted its stake in PROCEPT BioRobotics by 98.2% during the 1st quarter. Principal Financial Group Inc. now owns 20,983 shares of the company’s stock worth $1,037,000 after acquiring an additional 10,395 shares during the last quarter. Institutional investors own 89.46% of the company’s stock.

PROCEPT BioRobotics Stock Performance

PRCT opened at $68.95 on Friday. The company has a debt-to-equity ratio of 0.20, a current ratio of 7.51 and a quick ratio of 6.49. The company has a market capitalization of $3.55 billion, a price-to-earnings ratio of -32.52 and a beta of 1.03. The business’s 50-day moving average price is $75.48 and its two-hundred day moving average price is $66.35. PROCEPT BioRobotics Co. has a 1 year low of $24.83 and a 1 year high of $85.81.

PROCEPT BioRobotics (NASDAQ:PRCT) last announced its earnings results on Thursday, August 1st. The company reported ($0.50) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.02. The business had revenue of $53.35 million for the quarter, compared to analyst estimates of $50.10 million. PROCEPT BioRobotics had a negative return on equity of 37.85% and a negative net margin of 58.73%. PROCEPT BioRobotics’s revenue for the quarter was up 61.2% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.56) EPS. Equities analysts expect that PROCEPT BioRobotics Co. will post -1.88 EPS for the current fiscal year.

Insider Buying and Selling

In other PROCEPT BioRobotics news, CFO Kevin Waters sold 25,000 shares of PROCEPT BioRobotics stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $72.47, for a total value of $1,811,750.00. Following the sale, the chief financial officer now directly owns 96,096 shares in the company, valued at approximately $6,964,077.12. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, CFO Kevin Waters sold 25,000 shares of the firm’s stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $72.47, for a total value of $1,811,750.00. Following the completion of the transaction, the chief financial officer now directly owns 96,096 shares of the company’s stock, valued at approximately $6,964,077.12. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Antal Rohit Desai sold 35,220 shares of the company’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $76.12, for a total transaction of $2,680,946.40. Following the sale, the director now directly owns 23,963 shares in the company, valued at $1,824,063.56. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 179,892 shares of company stock worth $13,946,415. 17.40% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

PRCT has been the subject of several recent analyst reports. Truist Financial upped their target price on shares of PROCEPT BioRobotics from $74.00 to $95.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Piper Sandler reiterated an “overweight” rating and set a $75.00 target price on shares of PROCEPT BioRobotics in a report on Tuesday, October 8th. Bank of America increased their price target on PROCEPT BioRobotics from $80.00 to $94.00 and gave the stock a “buy” rating in a report on Thursday, August 22nd. TD Cowen lifted their price objective on PROCEPT BioRobotics from $75.00 to $99.00 and gave the company a “buy” rating in a report on Monday, September 16th. Finally, Wells Fargo & Company increased their target price on PROCEPT BioRobotics from $67.00 to $69.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, PROCEPT BioRobotics presently has an average rating of “Buy” and a consensus price target of $86.40.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).